Industry Policy and Environment - The core patent for Semaglutide is set to expire after March 2026, leading to increased market competition, with Jiuyuan Gene being one of the companies applying for this product [1] Product Development Progress - The clinical trial application for the innovative drug JY54 injection (a long-acting insulin analog) was accepted on February 9, 2026, aimed at weight management for obese or overweight populations, with subsequent trial initiation and data disclosure being noteworthy [1] Funding Movements - The company has been actively repurchasing shares since January 2026, including the repurchase of 854,000 shares on February 5 at a cost of 8.7731 million HKD, which may reflect management's outlook on business prospects [2]
九源基因2026年关注点：司美格鲁肽专利到期与新品临床试验